Adam Crystal, President, R&D at Tango Therapeutics, Inc. (TNGX), sold 27,000 shares at $22.25 ($618K) on 2026-06-01, disclosed to the SEC on 2026-06-03.
Scheduled sale ($618k) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.25 | 6,140 | $137K | 22.1% |
| 2 | $23.06 | 20,860 | $481K | 77.9% |
| Total | $22.87 avg | 27,000 | $618K | 100% |
| Filing → |
| TNGX | SELL | 2026-08-05 | $736K | — | Filing → |
| TNGX | SELL | 2026-07-02 | $799K | — | Filing → |
| TNGX | SELL | 2026-05-05 | $573K | — | Filing → |